Co-Diagnostics Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Co-Diagnostics ha un patrimonio netto totale di $63.8M e un debito totale di $0.0, che porta il suo rapporto debito/patrimonio netto a 0%. Le sue attività totali e le sue passività totali sono rispettivamente $72.4M e $8.6M.

Informazioni chiave

Rapporto debito/patrimonio netto

US$0

Debito

Indice di copertura degli interessi	n/a
Contanti	US$37.66m
Patrimonio netto	US$63.78m
Totale passività	US$8.60m
Totale attività	US$72.38m

Aggiornamenti recenti sulla salute finanziaria

Here's Why We're Watching Co-Diagnostics' (NASDAQ:CODX) Cash Burn Situation

Jun 14

Recent updates

Here's Why We're Watching Co-Diagnostics' (NASDAQ:CODX) Cash Burn Situation

Jun 14

One Co-Diagnostics, Inc. (NASDAQ:CODX) Analyst Just Slashed Their Estimates By A Consequential 14%

May 18

A Look At The Intrinsic Value Of Co-Diagnostics, Inc. (NASDAQ:CODX)

Apr 14

Co-Diagnostics: Hold Thesis Remains Well Intact

Sep 07

Co-Diagnostics stock sinks ~37% after hours on Q2 results miss, hurt by lower volumes

Aug 11

Co-Diagnostics, Inc. (NASDAQ:CODX) Shares Could Be 29% Below Their Intrinsic Value Estimate

Mar 28

Co-Diagnostics: Swinging For The Fences

Jan 24

Does Co-Diagnostics (NASDAQ:CODX) Deserve A Spot On Your Watchlist?

Dec 28

Why Co-Diagnostics Is A Solid Covid-19 Play

Aug 19

Co-Diagnostics, Inc.'s (NASDAQ:CODX) Share Price Boosted 42% But Its Business Prospects Need A Lift Too

Aug 14

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( $40.1M ) di CODX superano le sue passività a breve termine ( $5.8M ).

Passività a lungo termine: Le attività a breve termine di CODX ( $40.1M ) superano le sue passività a lungo termine ( $2.8M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: CODX è esente da debiti.

Riduzione del debito: CODX non aveva debiti 5 anni fa.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: CODX ha una pista di cassa sufficiente per più di un anno in base al suo attuale flusso di cassa libero.

Previsione Cash Runway: CODX ha una liquidità sufficiente per 1.3 anni se il flusso di cassa libero continua a ridursi ai tassi storici del 16.9 % ogni anno.

Co-Diagnostics Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Here's Why We're Watching Co-Diagnostics' (NASDAQ:CODX) Cash Burn Situation

Recent updates

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Co-Diagnostics, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Consensus revenue estimates increase by 143%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Co-Diagnostics, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Co-Diagnostics, Inc., Annual General Meeting, Aug 29, 2024

Co-Diagnostics, Inc. Submits First FDA 510(k) Application for Co-Dx PCR Pro Platform

Here's Why We're Watching Co-Diagnostics' (NASDAQ:CODX) Cash Burn Situation

New minor risk - Share price stability

First quarter 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Shareholder dilution

Co-Diagnostics, Inc. to Report Q1, 2024 Results on May 09, 2024

Co-Diagnostics, Inc. Appoints Executive Appointments

Full year 2023 earnings released

New major risk - Revenue and earnings growth

Co-Diagnostics, Inc. to Report Q4, 2023 Results on Mar 14, 2024

Co-Diagnostics, Inc. Completes Submission to FDA for Co-Dx PCR Pro

Chairman exercised options and sold US$58k worth of stock

Consensus revenue estimates increase by 474%

Price target increased by 50% to US$3.00

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Co-Diagnostics, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Co-Diagnostics, Inc. Appoints Ivory Chang as Chief Regulatory Affairs Officer

Consensus revenue estimates fall by 43%

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Co-Diagnostics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Co-Diagnostics, Inc., Annual General Meeting, Aug 30, 2023

Co-Diagnostics, Inc. Receives Funding for Co-Dx PCR Home Platform from NIH RADx Tech Program

One Co-Diagnostics, Inc. (NASDAQ:CODX) Analyst Just Slashed Their Estimates By A Consequential 14%

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Co-Diagnostics, Inc. to Report Q1, 2023 Results on May 11, 2023

A Look At The Intrinsic Value Of Co-Diagnostics, Inc. (NASDAQ:CODX)

Consensus revenue estimates fall by 83%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment improves as stock rises 16%

Chairman exercised options and sold US$111k worth of stock

Consensus revenue estimates fall by 14%

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Co-Diagnostics, Inc. Appoints Dr. Mark Poritz as New Chief Scientific Officer

Co-Diagnostics, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Investor sentiment improved over the past week

Pomerantz Law Firm Announces the Filing of a Class Action Against Co-Diagnostics, Inc. and Certain Officers

Co-Diagnostics: Hold Thesis Remains Well Intact

Investor sentiment deteriorated over the past week

Kaplan Fox & Kilsheimer LLP Files Class Action Suit in the United States District Court for the Southern District of New York Against Co-Diagnostics, Inc

Price target decreased to US$15.33

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Co-Diagnostics stock sinks ~37% after hours on Q2 results miss, hurt by lower volumes

Co-Diagnostics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Co-Diagnostics, Inc., Annual General Meeting, Aug 31, 2022

Co-Diagnostics spikes on shipments of monkeypox test

Estimating The Intrinsic Value Of Co-Diagnostics, Inc. (NASDAQ:CODX)

Investor sentiment improved over the past week

Now 20% undervalued after recent price drop

Co-Diagnostics: Well Priced, Long-Term Value Remains Too Distant

Now 24% undervalued after recent price drop

Co-Diagnostics, Inc. Completes Principal Design of Test for Monkeypox Virus

Chairman exercised options and sold US$59k worth of stock

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Investor sentiment deteriorated over the past week

Price target decreased to US$19.33

High number of new and inexperienced directors

Investor sentiment deteriorated over the past week

Co-Diagnostics: Where's Eikon?

High number of new and inexperienced directors

Consensus EPS estimates increase by 36%

Co-Diagnostics, Inc. (NASDAQ:CODX) Shares Could Be 29% Below Their Intrinsic Value Estimate

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Co-Diagnostics: Swinging For The Fences

Investor sentiment deteriorated over the past week

Co-Diagnostics, Inc. (NasdaqCM:CODX) completed the acquisition of Advanced Conceptions, Inc.